Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -

Israeli - Kiingereza - Ministry of Health

novo nordisk ltd., israel - insulin aspart - suspension for injection - insulin aspart 100 u/ml - insulin aspart - insulin aspart - novomix 50 is indicated for treatment of diabetes mellitus in adults.

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - protamine crystallised insulin asparte; soluble insulin asparte -

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes - novorapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Israeli - Kiingereza - Ministry of Health

novo nordisk ltd., israel - insulin aspart - solution for injection - insulin aspart 100 u/ml - insulin aspart - treatment of patients with diabetes mellitus in adults, adolescents and children aged 2 years and above.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 12.57 mg - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 8.01 mg - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 3.26 mg - injection - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 1.74 mg - injection - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients with: inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.